Abstract
A six-yr-old boy developed PRES after induction chemotherapy for the relapse of acute lymphoblastic leukemia. Two months after PRES, he underwent BMT from an unrelated HLA-mismatched donor. There were many risk factors for PRES in the BMT including the long-term use of FK506 and methylprednisolone, grade III graft-versus-host disease, thrombotic microangiopathy, and sepsis. Prophylactic treatment for hypertension with nicardipine in conjunction with close monitoring of the magnesium level and the use of valproic acid might be an effective management approach to prevent post-transplant PRES.
© 2010 John Wiley & Sons A/S.
MeSH terms
-
Anticonvulsants / therapeutic use*
-
Antihypertensive Agents / therapeutic use*
-
Brain / diagnostic imaging
-
Brain / pathology
-
Child
-
Hematopoietic Stem Cell Transplantation / adverse effects*
-
Humans
-
Hypertension / etiology
-
Hypertension / prevention & control*
-
Magnetic Resonance Imaging
-
Male
-
Posterior Leukoencephalopathy Syndrome / diagnosis
-
Posterior Leukoencephalopathy Syndrome / etiology*
-
Posterior Leukoencephalopathy Syndrome / prevention & control*
-
Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
-
Radiography
-
Seizures / etiology
-
Seizures / prevention & control*
-
Transplantation, Homologous
-
Unrelated Donors
Substances
-
Anticonvulsants
-
Antihypertensive Agents